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Abstract
C-reactive protein (CRP), a biomarker of inflammation, has been associated with increased 
disease activity in rheumatoid arthritis. However, the association in systemic lupus erythematosus 
(SLE) remains unclear. We examined the association of CRP with self-reported disease activity in 
the Carolina Lupus Study and described differences by sociodemographic characteristics. The 
study included baseline and three-year follow-up data on 107 African-American and 69 Caucasian 
SLE patients enrolled at a median 13 months since diagnosis. Models estimated prevalence 
differences in the association of baseline CRP with self-reported flares, adjusting for age, sex, race 
and education. Active disease or flare was reported by 59% at baseline and 58% at follow-up. 
Higher CRP (>10 μg/ml vs. <3 μg/ml) was associated with a 17% (95% CI: −20, 53%) higher 
prevalence of flare at baseline and a 26% (95% CI: −9, 62%) higher prevalence of flare at follow-
up. These CRP-flare associations were notably stronger in patients with lower education at 
baseline and in African Americans at follow-up. These findings suggest CRP may be a useful 
marker in studies of SLE health disparities.
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Introduction
C-reactive protein (CRP), a biomarker of inflammation, has a debated role in the disease 
course of patients with systemic lupus erythematosus (SLE).1–4 In other autoimmune 
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diseases, such as rheumatoid arthritis, CRP has been associated with increased disease 
activity,5–7 but SLE findings are inconsistent. Higher CRP has been seen in African-
American SLE patients and those with lower socioeconomic status.8 In the general 
population, CRP has also been reported to be higher in African Americans compared to 
Caucasians.9, 10 African Americans have a higher incidence of SLE and, on average, 
increased disease activity and severity compared to Caucasians.11 It is unknown whether 
racial/ethnic and socioeconomic differences in CRP are related to disparities in SLE disease 
activity and outcomes.
In the Carolina Lupus Study (CLU), we previously described a higher index of early disease 
damage in African American and patients with a lower household income.12 Here, in a 
secondary analysis in the same cohort, we examined whether baseline CRP was associated 
with self-reported active disease or flares at baseline and follow-up. Additional analyses 
explored sociodemographic differences.
Patients and methods
Study population and design
Carolina Lupus Study (CLU) is a population-based cohort study of SLE patients age 18 
years and older diagnosed between January 1, 1995, and July 31, 1999, based on the 1997 
ACR classification criteria.13, 14 Recruitment procedures and demographic characteristics 
have been described previously.15 Eligible patients resided in the study area (60 continuous 
counties in North Carolina and South Carolina) for at least 6 months prior to diagnosis and 
were identified through referrals from university and community based rheumatologists. Of 
the 285 patients identified, 93% (n=265) enrolled in the study and completed baseline 
interviews (median time from SLE diagnosis to enrollment: 13 months). A telephone 
questionnaire was administered in 2001, after a median follow-up of 39 months, with 75% 
of the patients participating (n=187). Overall, those lost to follow-up had higher C-reactive 
protein (CRP) levels at baseline (mean 10.7 μg/ml vs. 8.2 μg/ml in patients not lost to 
follow-up), and 25% died prior to the follow-up interview. Patients with baseline data on 
CRP and data on flare at baseline or follow-up were included in this analysis (n=176). Three 
patients did not have data available on baseline flare, and two patients did not have data on 
follow-up flare. These patients were included in the analyses for which flare data were 
available.
Procedures and measures
Baseline data—Questionnaire data were collected through in-person interviews and 
included demographics (age, sex, self-reported race/ethnicity and education) and smoking 
status. Blood samples were drawn from 92% of patients. Serum CRP was measured by 
ELISA (enzyme-linked immunosorbent assay) with a lower limit of detection of 20 ng/ml 
and sera were tested for anti-native DNA antibody (anti-dsDNA) using fixed Crithidia 
luciliae immunofluorescence, as previously described.16, 17 Self-reported active disease or 
flare at baseline was assessed by asking the patient: Since you were first sick, have you had 
periods of flare and remission, or has your disease been fairly constant (flare and remission, 
or fairly constant)? Are you currently having a flare-up or are you in remission (flare-up or 
Eudy et al. Page 2






















remission)? Responses were categorized as (0) remission or (1) active disease or flare. 
Clinical and immunologic features of SLE, including serositis, arthritis, and biopsy-
confirmed lupus nephritis at baseline, were abstracted from medical records by a single 
abstracter.
Follow-up data—Telephone follow-up interviews collected data on the primary outcome 
variable, disease flare, and health insurance (Medicaid/Medicare or private insurance). 
Disease flare at follow-up was determined by asking the patient: In the past 3 months, have 
you had a lupus flare (a lupus flare is when your lupus gets worse) (Yes/No)? Responses 
were categorized as (0) no flare or (1) flare within three months prior to follow-up.
The follow-up questionnaire included the previously validated Systemic Lupus 
Erythematosus Activity Questionnaire (SLAQ) and the patient global assessment (PGA) of 
disease activity in the previous three months. SLAQ included questions on 24 SLE 
symptoms, and a score of 1 was given to any symptom that was present.18, 19 The PGA of 
disease activity was captured by the question: Please rate the activity of your lupus during 
the past three months: 0 (no activity) to 10 (most activity).18 For 127 patients (72% of the 
study sample) data on SLE damage were collected from medical records by a single, trained 
abstracter using the Systemic Lupus International Collaborating Clinics (SLICC)/American 
College of Rheumatology (ACR) Damage Index (SDI).12 Damage was defined as 
irreversible change, not related to active inflammation, occurring since the diagnosis of SLE 
and present for at least six months.20
Statistical analyses
Prevalence of flare/active disease at baseline and flare at follow-up were estimated using 
baseline CRP categorical cut-points to allow interpretation in a clinical context: CRP < 3.0 
μg/ml; 3 ≤ CRP < 10 μg/ml; and CRP > 10 μg/ml.21 Education was used as an indicator of 
socioeconomic status since it may predict future occupation and wages, while being less 
influenced by age- or disease-related changes in these characteristics.22, 23 Education was 
coded as high school (HS) diploma or less (low education; ≤ HS) and greater than high 
school diploma (high education; > HS). Race/ethnicity, sex, education and age variables 
were centered so the intercept of regression models represented the average patient in the 
study (i.e., an African-American woman aged 42.5 years with some college).
Effect measure modifiers were determined by a likelihood ratio test (α=0.20). Confounding 
was defined as a 10% change-in-estimate of beta when included in the model. Age, sex, race 
and education were included in final models to adjust for confounding. Models stratified by 
education (i.e., ≤ HS or > HS) were also adjusted for education (<12 years, 12 years, some 
college or vocational training, and college graduate or higher) to control for residual 
confounding created by dichotomizing the variable.24 Smoking and health insurance status 
were not included in the final models as neither were a confounder or modifier.
Linear-risk regression models estimated prevalence, prevalence difference (PD) and 95% 
confidence interval (CI) for the cross-sectional association of CRP with active disease at 
baseline and the prospective association of baseline CRP with flare at follow-up, adjusting 
for age, sex, race/ethnicity and education to control for confounding. In statistical models for 
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flare at follow-up, baseline flare/active disease was not a confounder in the association of 
CRP and flare at follow-up and was excluded from the final model. In the subset of patients 
with available data, SDI score was not a confounder or effect modifier in the association of 
CRP and flare at follow-up. We examined bivariate relationships between clinical and 
immunological features of SLE (lupus nephritis, anti-dsDNA, serositis, arthritis, and 
baseline CRP) with the presence of baseline active disease/flare and with CRP categories 
using Chi-square test. To determine the preliminary association of baseline CRP and PGA 
score at follow-up, we used a linear regression model. CRP was analyzed on the natural log 
scale (lnCRP) to allow for normal distribution in regression models.
All analyses were performed using SAS software, version 9.2 (Cary, NC).
Results
In the Carolina Lupus Study cohort, 90% of patients were female and 61% African-
American (Table 1). African-American patients were significantly younger and more likely 
to have a lower education level compared to Caucasian. A greater percentage of African-
American (33%) compared to Caucasian patients (19%) had C-reactive protein (CRP) levels 
in the highest category (>10 μg/ml). Reported active disease/flare at baseline and follow-up 
did not vary by race/ethnicity or educational attainment. African Americans were more 
likely to have lupus nephritis and a higher SLICC/ACR Damage Index (SDI) score at 
follow-up (mean: 2.1) than Caucasians (mean: 0.9). No differences were seen by education.
CRP and active disease at baseline
Fifty-eight percent of patients reported active disease/flare at baseline (Table 2); of these, a 
greater proportion had arthritis compared to patients who did not report active disease/flare 
(80% vs. 65%), but no differences were seen for other clinical and immunologic features of 
SLE. Prevalence of arthritis and lupus nephritis did not increase with higher CPR levels. 
Serositis, however, was associated with higher CRP levels, with 59% of patients with CRP 
>10 μg/ml having serositis confirmed in their medical records at baseline, compared to 41% 
of patients with CRP <3 μg/ml. The prevalence of anti-dsDNA decreased with higher CRP.
The prevalence of flare/active disease increased with higher CRP levels at baseline when 
adjusting for age, sex, race and education (Table 3). In patients with CRP < 3 μg/ml, the 
adjusted prevalence for reported active disease/flare was 31%, compared to 47% in patients 
with CRP >10 μg/ml (prevalence difference (PD): 17% (95% CI: −20, 53%)). Among 
patients with a high school education or less, the adjusted prevalence of flare at baseline was 
26% for patients with CRP < 3 μg/ml compared to 71% with baseline CRP >10 μg/ml (PD: 
45%; 95% CI: −11, 102%), while no differences were noted among those with a higher 
education level. This represented a statistical interaction (likelihood ratio p-value = 0.08) of 
education on the association of CRP with self-reported disease activity. Race/ethnicity was 
not a modifier in the association of baseline CRP and flare/active disease at baseline 
(likelihood ratio p-value > 0.2).
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Baseline CRP and flare at follow-up
The adjusted prevalence of flare at follow-up increased with higher baseline CRP (Table 3), 
from 46% for patients with a baseline CRP < 3 μg/ml to 72% for patients with baseline CRP 
>10 μg/ml (PD: 26%; 95% CI: −9, 62%). Only 36% of participants reported both active 
disease/flare at baseline and flare at follow-up, and the association of baseline CRP and flare 
at follow-up was not substantially attenuated after adjusting for baseline flare (results not 
shown). Among African-American patients, there was a positive association of baseline 
CRP and prevalence of flare at follow-up. Prevalence differences for CRP levels of 3–10 
μg/ml and >10 μg/ml compared to < 3 μg/ml were 26% (95% CI: 2, 50%) and 52% (95% CI: 
5, 99%), respectively. This pattern was not seen in Caucasians (statistical interaction 
likelihood ratio test p-value=0.05). Education was not a modifier in the association of CRP 
with prevalence of flare at follow-up (likelihood ratio p-value > 0.2).
The Patient Global Assessment (PGA) of disease activity score at follow-up was 
significantly higher in patients reporting a recent flare than those who did not report a flare 
(Table 4). PGA scores were significantly higher in patients with higher CRP; in linear 
models (not shown), for every 1-μg/ml increase in natural-log transformed baseline CRP 
(lnCRP), there was a 0.4 unit increase in PGA score at follow-up. A similar pattern was seen 
for the SLE Activity Questionnaire (SLAQ) score, with patients who reported a flare at 
follow-up having a higher mean SLAQ score. No racial/ethnic or educational differences 
were seen for either disease activity score.
Discussion
These results provide evidence that higher C-reactive protein (CRP) was associated with a 
greater prevalence of self-reported flares at baseline and flares at follow-up. This is similar 
to the finding from another SLE cohort showing higher CRP was associated with increased 
concurrent disease activity.25 Hence, in addition to being a marker of current disease status, 
our findings suggest CRP may also predict future disease activity.
Our results are consistent with other studies that show higher CRP levels in African 
Americans compared to Caucasians, as well as in patients with lower education.10, 26 
Although the literature suggests that African Americans have increased disease activity in 
comparison to Caucasians,11 our results show no difference in self-reported baseline active 
disease/flare and flare at follow-up by race/ethnicity or education. Despite relatively limited 
statistical power, our analyses revealed substantial effect measure modification by 
educational attainment and race/ethnicity. These findings suggest that the pathways and 
underlying causes of disease flares may differ by sociodemographic factors, highlighting the 
need to understand the etiology of disparities in inflammation and outcomes in SLE patients.
One explanation for the racial/ethnic or socioeconomic differences in the association of CRP 
and disease activity/flare could be the operation of an underlying factor, such as 
psychosocial stress, influencing the relationship of CRP with disease activity and flare in 
African-American patients and patients with lower educational attainment. Both chronic and 
daily interpersonal stress have been associated with higher CRP27, 28 and have also been 
associated with certain symptoms of SLE.29 Preliminary results of additional data collected 
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in the our cohort’s follow-up interviews show that a higher proportion of African Americans 
and patients with lower educational attainment felt the need to squelch their anger at least 
daily. Better understanding is needed of the effects of stress on flare, and the 
interrelationship of CRP, flares, and stress in SLE patients, and how these factors may 
contribute to disparities in disease damage and long-term outcomes.
Health care bias may be another underlying factor. Medicare/Medicaid status was not a 
confounder in the present analysis, but the types of medications prescribed to patients may 
differ by race/ethnicity. A previous study found a higher proportion of Caucasian compared 
to African-American patients received the anti-malarial hydroxychloroquine during the first 
5 years after diagnosis.30 Anti-malarial medications have been associated with lower CRP 
levels,1 and if Caucasian patients in the present study were prescribed these drugs more 
often than African-American, this may have influenced the observed racial differences in the 
relationship of CRP and flare at follow-up. Differences by clinical features seemed unlikely 
to bias the observed associations.
Our results support a previous study of ter Borg et al.,31 which found that CRP levels 
increased during episodes of serositis. We found that the prevalence of serositis reported in 
the medical records of patients was associated with a higher baseline CRP, which was more 
pronounced in African-American patients and patients with less than a high school 
education (results not shown). Notably, we did not see any evidence of higher CRP in 
patients with arthritis or lupus nephritis, nor did we observe confounding by SDI.
The present study is limited by a lack of available baseline data on medications and body 
mass index (BMI), both of which may be important factors in the pathway relating CRP and 
disease activity or flares. Lee, et al8 suggested that analyses of C-reactive protein and 
cardiovascular disease in SLE patients should adjust for BMI, ethnicity, education, disease 
activity and medications, as they were associated with both CRP and cardiovascular disease. 
Our results may over-estimate the true association, if BMI and medication are confounders 
in the present analysis. Medication data would also be important in fully understanding the 
pattern we saw of the prevalence of anti-dsDNA decreasing with higher CRP. The study is 
also limited by the small sample size and, therefore, relatively low power. Several of the 
adjusted prevalence difference confidence intervals expanded beyond 0 and 100%, so 
estimated prevalence differences are imprecise.
Notably, those patients who were lost to follow-up, and not included in these analyses, had 
higher baseline CRP levels and lower education than those who remained in the study. If 
they also had higher disease activity, our estimates of the CRP-disease activity association 
may be lower than if they had been contacted earlier (i.e., in those who died before follow-
up) or had otherwise remained in the cohort.
Comparisons of self-reported activity with standardized patient global assessment (PGA) of 
disease activity and Systemic Lupus Erythematosus Activity Questionnaire (SLAQ) scores 
gave us confidence in our primary outcome measure and observed associations. However, 
the study would have benefited from the collection of data from standardized, clinical 
disease activity measures, such as SLEDAI, SLAM, or BILAG, in addition to self-reported 
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disease activity/flare. Previous studies have found discrepancies between a physician’s 
assessment of a patient’s SLE disease activity and the patient’s own assessment.32–35 
Patients tend to score their disease activity higher than a physician and place weight on 
subjective manifestations of disease, such as poor self-perceived function (both physical and 
mental) and arthritis, while physicians base their assessment on more objective findings, 
such as laboratory data or current medications. This is supported in our cohort, with the 
prevalence of arthritis higher in patients who reported baseline active disease/flare. 
Additionally, physicians make their assessment of a patient’s disease activity based on their 
overall knowledge of SLE and experience with other patients, while most patients’ 
assessments are in comparison to their own previous physical and mental manifestations.
Nevertheless, patients’ perceptions of disease activity may have implications for disease 
outcomes, as shown by a prospective study of SLE patients that found mental health and 
physical functions reported by patients in the Medical Outcomes Study SF-20+ predicted 
death or increased organ system damage after 5 years.36 In an exploratory analysis of the 
subset of 127 patients with SDI scores, we found that self-reported flare at baseline was 
related to a higher SDI score at follow-up (1.7 vs. 1.3 in patients reporting no baseline flare 
or active disease), and overall, SDI score at follow-up increased 7% for every one μg/ml 
increase in baseline natural log-transformed CRP (results not shown).
In sum, our findings offer insight into a relationship that is not well understood in the SLE 
literature. Long-term follow-up of the Carolina Lupus Cohort provides a unique opportunity 
to elucidate racial/ethnic and socioeconomic disparities in a representative patient 
population, including a high proportion of African Americans and referrals from 
community-based physicians. Despite modest sample size, the effects were saw in the 
analysis were strong enough to show a significant association. Larger studies, with more 
extensive clinical data, are needed to confirm our findings of racial and educational 
differences in the relationship of CRP and disease activity in SLE patients. Understanding 
these relationships may help identify underlying risk factors and sources of disparities in 
SLE.
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Appendix 1
Abbreviations
ACR American College Rheumatology
ANOVA analysis of variance
Anti-dsDNA anti-native DNA antibody
BILAG British Isles Lupus Assessment Group index
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BMI body mass index
CI confidence interval
CLU Carolina Lupus Study
CRP C-reactive protein
ELISA enzyme-linked immunosorbent assay
HS high school





PGA Patient Global Assessment
SC South Carolina
SD standard deviation
SDI Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology Damage Index
SLAM Systemic Lupus Activity Measure
SLAQ Systemic Lupus Erythematosus Activity Questionnaire
SLE systemic lupus erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLICC Systemic Lupus International Collaborating Clinics
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Table 4
Mean distribution of Patient Global Assessment (PGA) and SLE Activity Questionnaire (SLAQ) Scores 
(n=174)a
PGA (0–10 scale) SLAQ (0–24 scale)
Mean (SD) p-value Mean (SD) p-value
Self-reported follow-up flare
 Yes 5.8 (2.5) <0.001b 13.0 (4.6) <0.001b
 No 2.9 (2.2) 7.3 (4.7)
Race
 African-American 4.8 (2.9) 0.1b 10.7 (5.7) 1.0b
 Caucasian 4.2 (2.5) 10.7 (4.7)
Education
 High school education or less 4.6 (2.9) 1.0b 10.1 (5.5) 0.6b
 Greater than high school 4.6 (2.7) 11.2 (5.2)
Baseline CRP
 <3 3.9 (2.8) 0.02c 9.8 (5.3) 0.2c
 3–10 4.5 (2.6) 10.6 (5.0)
 >10 5.5 (2.8) 11.8 (5.8)
a
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